Sigyn Therapeutics (SIGY) Other Non Operating Income (2017 - 2025)
Sigyn Therapeutics (SIGY) posted Other Non Operating Income of $5797.0 for Q2 2025, up 189.85% sequentially from $2000.0 in Q2 2020.
Sigyn Therapeutics (SIGY) Other Non Operating Income (2017 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Other Non Operating Income for 4 years, with the latest figure at $5797.0 in Q2 2025.
- Quarterly Other Non Operating Income changed N/A year-over-year to $5797.0 in Q2 2025, while the trailing twelve-month figure through Sep 2025 was $7797.0 (changed N/A YoY) and the FY2018 annual result came in at -$535039.0, up 22.61% from the prior year.
- Other Non Operating Income grew to $5797.0 in Q2 2025 per SIGY's latest filing, from $2000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $5797.0 in Q2 2025 and troughed at $5797.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 5,797.00 |
| Jun 30, 2020 | 2,000.00 |
| Dec 31, 2018 | -10,581.00 |
| Sep 30, 2018 | 23,966.00 |
| Jun 30, 2018 | -192,945.00 |
| Mar 31, 2018 | -548,425.00 |
| Dec 31, 2017 | -974,856.00 |
| Sep 30, 2017 | 531,010.00 |
| Jun 30, 2017 | -282,317.00 |
| Mar 31, 2017 | 45,762.00 |